Give And Take As China Finalizes Biosimilars Guideline
This article was originally published in PharmAsia News
Three months after publishing a draft guideline on biosimilars, China's Food and Drug Administration (CFDA) has just released the final official version, although it is still dubbed a pilot scheme. The new guideline may superficially look similar to the draft, but a closer comparison reveals some key differences.
You may also be interested in...
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Early Research Suggests Wearables Can Spot Early Signs Of COVID-19; Fitbit Receives $2.5m Army Award
A consortium of researchers, including Fitbit, are developing algorithms to spot COVID-19 before people become ill.
The firm’s major product revenues bounced back from the pandemic-troubled second quarter, with Botox recovering as predicted.